Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AIM ImmunoTech (AIM) Accounts Payables (2018 - 2025)

Historic Accounts Payables for ImmunoTech (AIM) over the last 11 years, with Q3 2025 value amounting to $1.3 million.

  • ImmunoTech's Accounts Payables fell 8001.28% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 8001.28%. This contributed to the annual value of $6.4 million for FY2024, which is 93.12% down from last year.
  • According to the latest figures from Q3 2025, ImmunoTech's Accounts Payables is $1.3 million, which was down 8001.28% from $7.3 million recorded in Q2 2025.
  • ImmunoTech's 5-year Accounts Payables high stood at $7.3 million for Q2 2025, and its period low was $1.3 million during Q3 2025.
  • For the 3-year period, ImmunoTech's Accounts Payables averaged around $5.2 million, with its median value being $6.3 million (2024).
  • As far as peak fluctuations go, ImmunoTech's Accounts Payables soared by 15360.3% in 2024, and later crashed by 8001.28% in 2025.
  • ImmunoTech's Accounts Payables (Quarter) stood at $6.4 million in 2023, then dropped by 0.93% to $6.4 million in 2024, then crashed by 80.39% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q3 2025, $7.3 million for Q2 2025, and $6.9 million during Q1 2025.